Abstract
Breast cancer is a complex disease posing a serious threat to the female population worldwide. A complex molecular landscape and tumor heterogeneity render breast cancer cells resistant to drugs and able to promote metastasis and invasiveness. Despite the recent advancements in diagnostics and drug discovery, finding an effective cure for breast cancer is still a major challenge. Positive and negative regulation of apoptosis has been a subject of extensive study over the years. Numerous studies have shed light on the mechanisms that impede the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) signaling cascade. Long non-coding RNAs (lncRNAs) have been implicated in the orchestration, development, proliferation, differentiation and metastasis of breast cancer. However, the roles of lncRNAs in fine-tuning apoptosis regulating machinery in breast cancer remain to be elucidated. The present review illuminates the roles of these molecules in the regulation of breast cancer and the interplay between lncRNA and TRAIL in breast cancer. The present review also attempts to reveal their role in the regulation of apoptosis in breast cancer appears a promising approach for the development of new diagnostic and therapeutic regimens.
Introduction: The Challenge of TRAIL Resistance
Breast cancer remains a leading cause of death among women due to its immense molecular heterogeneity and its ability to develop resistance to conventional drugs. One promising therapeutic target is TRAIL (tumor necrosis factor-related apoptosis-inducing ligand), a protein that can trigger "cell suicide" (apoptosis) specifically in cancer cells while leaving healthy cells untouched.
However, many breast cancers find ways to evade TRAIL-induced death. This review addresses the role of lncRNAs—RNA molecules longer than 200 nucleotides that do not code for proteins—in this evasion. Once dismissed as "junk DNA," lncRNAs are now recognized as critical regulators that can either help or hinder the TRAIL pathway. Understanding this interplay is essential for overcoming treatment resistance.
Mechanisms of lncRNA Regulation
As a comprehensive review, the authors synthesized findings from over 140 primary research papers. They categorized the roles of various lncRNAs based on several key regulatory mechanisms:
- Epigenetic Modulation: lncRNAs recruit chromatin-remodeling complexes (like PRC2) to silence or activate genes.
- Transcriptional Regulation: They can act as decoys, scaffolds, or guides to influence gene expression directly.
- Direct Caspase Interaction: Some lncRNAs inhibit or enhance the activity of "executioner" enzymes (caspases) that carry out the cell death program.
Key Insights: The "Double Agent" Nature of lncRNAs
lncRNAs aren't universally "good" or "bad." Their function is highly context-dependent:
- Oncogenic lncRNAs: Many promote tumor growth and TRAIL resistance. For instance, POU3F3 inhibits Caspase 9, and NEAT1 inhibits Caspase 3. When these lncRNAs are knocked down in the lab, the cells become sensitive to death again.
- Tumor Suppressor lncRNAs: Others, like GAS5, act as tumor suppressors by enhancing TRAIL expression through epigenetic modifications.
The TRAIL Signaling Tangle
The interaction between lncRNAs and the TRAIL pathway is intricate. lncRNAs like ANRIL and HOXA-AS2 use the TGF-β signaling pathway to suppress apoptosis and promote the growth of triple-negative breast cancer (TNBC). Conversely, restoring the expression of lncRNAs like XIST can reduce cell proliferation and induce apoptosis by inhibiting miR-454.
Clinical Implications and Future Directions
The review highlights several high-impact findings that point toward clinical utility:
- Biomarker Potential: Because lncRNAs are tissue-specific and detectable in "liquid biopsies" (blood/plasma), they offer a non-invasive way to monitor patient response to TRAIL-based therapies.
- Prognostic Value: High levels of HOTAIR are consistently linked to increased invasiveness and metastasis, particularly in ER+/PR+ breast cancers.
Limitations and Future Work
Despite the progress, several gaps remain:
- Subtype Specificity: The specific roles of lncRNAs across different molecular subtypes (Luminal A, Luminal B, HER2-type) are not yet fully elucidated.
- Mechanism Gaps: For some lncRNAs, like GAS5, the exact biochemical mechanisms triggering apoptosis remain a mystery.
- Clinical Translation: Most current evidence is from in vitro or in vivo models. Transitioning these findings into human clinical trials for lncRNA-based therapeutics is the next major hurdle for the field.
Summary updated